Please assess the completion status of the following clinical trial:

Trial Title: Study of IMC-EB10 in Participant With Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The participant has acute myeloid leukemia in the bone marrow or blood that has relapsed with or without a prior complete remission~2. The participant is not regarded to be a candidate for a potentially curative, higher priority treatment for acute myeloid leukemia~3. The participant has resolution of all clinically significant toxic effects of any prior antitumor therapy and any other study-specific clinical or laboratory parameter specified in the entry criteria~4. The participant has not had major surgery, an open biopsy, a significant injury, and/or prior antitumor therapy (except antileukemia therapy) within 21 days prior to the first infusion of IMC-EB10~5. The participant has an Eastern Cooperative Oncology Group (ECOG)performance status of 0, 1, or 2 at study entry.~6. The participant is age 18 years or older~7. The participant has a life expectancy of \>3 months~8. The participant has adequate liver and kidney function, as defined in the entry criteria~9. The participant is using an effective contraception (per the institutional standard), if procreative potential exists~10. The participant is able to give written informed consent~11. The participant is willing and able to comply with study procedures, scheduled visits, and treatment plans~Exclusion Criteria:~1. The participant has had prior allogenic or autologous stem cell transplant within \<3 months of the first infusion of IMC-EB10~2. The participant has had an organ transplant (nonhematologic) within 3 years of study entry~3. The participant has active central nervous system leukemia~4. The participant has extramedullary disease without peripheral/and or bone marrow involvement~5. The participant is disease-free from a previous or concurrent malignancy for a period ≤ 1 year. A participant who has basal cell carcinoma or carcinoma in situ of the cervix will not be excluded from the study~6. The participant is currently receiving antileukemia therapy. Concurrent treatment with hydroxyurea is permitted~7. The participant has uncontrolled intercurrent illness as specified in the study entry criteria~8. The participant is receiving chronic steroid or other immunosuppressive medications. Occasional use of steroid-containing medications for, for example (e.g.), asthma exacerbation or for skin lesions, is permitted~9. The participant is receiving full-dose heparin (including low molecular weight heparin) or warfarin. \[The participant is permitted to use low-dose warfarin to maintain patency of preexisting, permanent, indwelling intravenous (I.V.) catheters.\]~10. The participant is pregnant (confirmed by urine or serum pregnancy test) or breast feeding~11. The participant has received treatment with monoclonal antibodies within 6 weeks prior to first infusion of IMC-EB10~12. The participant has a history of clinically significant allergic reactions to monoclonal antibodies or other therapeutic proteins

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IMC-EB10 5 milligrams/kilogram (mg/kg) (Type: EXPERIMENTAL): All participants will receive intravenous infusions of IMC-EB10, with the dose depending on which cohort they are enrolled into.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy